FDA Issues New Guidance on Drug Naming
By EsqSocial Corporation 18/12/20
Last week, the Food and Drug Administration (“FDA”) issued a pair of Guidance for Industry documents outlining best practices for developing proprietary names (i.e. brand names) for prescription and nonprescription human drug products. The documents provide the agency’s current framework and recommendations for the notoriously unpredictable approval process for drug brand names that do not contribute to medication errors, particularly those attributable to nomenclature issues....
By: Mintz - Trademark & Copyright Viewpoints